Saito Y, Nazif T, Baumbach A, et al. - Given the necessity of balancing adjunctive antithrombotic treatment use to decrease thrombotic risks in patients undergoing transcatheter aortic valve replacement (TAVR) against bleeding complications, because both are related to increased mortality, researchers focused on adjunctive antithrombotic therapy as a treatment option in this patient population. The regimen suggested by the guidelines is dual antiplatelet therapy for 3 to 6 months post-TAVR but current evidence does not support this practice well. The possible superior safety of single antiplatelet therapy over that of dual antiplatelet therapy was suggested, by current registry-based evidence, in patients with no indication for oral anticoagulation. In cases where oral anticoagulant use is indicated, oral anticoagulation monotherapy seemed to be superior to anticoagulation plus antiplatelet therapy. They found rather scarce evidence for adjunctive antithrombotic therapy although TAVR procedures are being increasingly adopted as a management option in patients with severe aortic stenosis.